CY2012022I2 - Φαρμακο που περιεχει 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)φαινολη με επιβραδυμενη απελευθερωση δραστικης ουσιας - Google Patents
Φαρμακο που περιεχει 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)φαινολη με επιβραδυμενη απελευθερωση δραστικης ουσιαςInfo
- Publication number
- CY2012022I2 CY2012022I2 CY2012022C CY2012022C CY2012022I2 CY 2012022 I2 CY2012022 I2 CY 2012022I2 CY 2012022 C CY2012022 C CY 2012022C CY 2012022 C CY2012022 C CY 2012022C CY 2012022 I2 CY2012022 I2 CY 2012022I2
- Authority
- CY
- Cyprus
- Prior art keywords
- dimethylamino
- phenol
- propyl
- ethyl
- methyl
- Prior art date
Links
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical compound CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10152469A DE10152469A1 (de) | 2001-10-24 | 2001-10-24 | 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung |
| DE2002148309 DE10248309A1 (de) | 2002-10-16 | 2002-10-16 | 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung |
| PCT/EP2002/011809 WO2003035053A1 (de) | 2001-10-24 | 2002-10-22 | 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2012022I1 CY2012022I1 (el) | 2015-08-05 |
| CY2012022I2 true CY2012022I2 (el) | 2015-08-05 |
Family
ID=26010444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2012022C CY2012022I2 (el) | 2001-10-24 | 2012-08-13 | Φαρμακο που περιεχει 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)φαινολη με επιβραδυμενη απελευθερωση δραστικης ουσιας |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US20050058706A1 (el) |
| EP (1) | EP1439829B1 (el) |
| JP (2) | JP4758064B2 (el) |
| KR (1) | KR100958045B1 (el) |
| CN (1) | CN100402021C (el) |
| AR (1) | AR036943A1 (el) |
| AT (1) | ATE303802T1 (el) |
| AU (1) | AU2002349001C1 (el) |
| BR (1) | BRPI0213653B8 (el) |
| CA (1) | CA2464578C (el) |
| CO (1) | CO5570662A2 (el) |
| CY (1) | CY2012022I2 (el) |
| DE (1) | DE50204198D1 (el) |
| DK (1) | DK1439829T3 (el) |
| EC (1) | ECSP045102A (el) |
| ES (1) | ES2248622T3 (el) |
| HU (1) | HU230161B1 (el) |
| IL (2) | IL161587A0 (el) |
| MX (1) | MXPA04003742A (el) |
| MY (1) | MY127797A (el) |
| NO (2) | NO331896B1 (el) |
| NZ (1) | NZ532999A (el) |
| PE (1) | PE20030527A1 (el) |
| PL (1) | PL216535B1 (el) |
| PT (1) | PT1439829E (el) |
| SI (1) | SI1439829T1 (el) |
| WO (2) | WO2003035054A1 (el) |
| ZA (1) | ZA200403928B (el) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| ES2640404T3 (es) | 2002-11-22 | 2017-11-02 | Grünenthal GmbH | Combinación de analgésicos seleccionados con inhibidores de la COX II |
| NZ545202A (en) * | 2003-08-06 | 2010-03-26 | Gruenenthal Chemie | Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| SI1612203T1 (sl) * | 2004-06-28 | 2007-12-31 | Gruenenthal Chemie | Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| KR101204657B1 (ko) * | 2004-07-01 | 2012-11-27 | 그뤼넨탈 게엠베하 | (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형 |
| DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| WO2007128412A1 (en) * | 2006-04-28 | 2007-11-15 | Grünenthal GmbH | Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid |
| RU2442576C2 (ru) * | 2006-04-28 | 2012-02-20 | Грюненталь Гмбх | Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол |
| CN101091725A (zh) * | 2006-06-23 | 2007-12-26 | 天津天士力制药股份有限公司 | 一种中药颗粒及其制备方法 |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
| DK2596784T3 (en) * | 2007-11-23 | 2017-03-06 | Gruenenthal Gmbh | Tapentadol compositions |
| EP2240431B1 (de) * | 2007-12-07 | 2017-01-25 | Grünenthal GmbH | Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| BRPI0906467C1 (pt) * | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
| PT2273983T (pt) | 2008-05-09 | 2016-10-28 | Gruenenthal Gmbh | Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização |
| US20100190752A1 (en) * | 2008-09-05 | 2010-07-29 | Gruenenthal Gmbh | Pharmaceutical Combination |
| EP2352494B1 (en) | 2008-10-30 | 2019-10-09 | Grünenthal GmbH | Novel and potent tapentadol dosage forms |
| MX2012000317A (es) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Forma de dosificacion de liberacion controlada extruida por fusion en caliente. |
| WO2011009604A1 (en) | 2009-07-22 | 2011-01-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US9579285B2 (en) * | 2010-02-03 | 2017-02-28 | Gruenenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of an extruder |
| JP5905872B2 (ja) * | 2010-04-07 | 2016-04-20 | ルピン・リミテッド | タペンタドールの制御放出医薬組成物 |
| WO2011138037A2 (de) * | 2010-05-05 | 2011-11-10 | Ratiopharm Gmbh | Festes tapentadol in nicht-kristalliner form |
| HUE026619T2 (en) * | 2010-06-15 | 2016-06-28 | Gruenenthal Gmbh | Pharmaceutical combination for the treatment of pain |
| AU2011273907B2 (en) | 2010-06-30 | 2015-03-19 | Grunenthal Gmbh | Tapentadol for use in the treatment of Irritable Bowel Syndrome |
| CN106831456A (zh) | 2010-07-23 | 2017-06-13 | 格吕伦塔尔有限公司 | 3‑(3‑二甲基氨基‑1‑乙基‑2‑甲基‑丙基)‑苯酚的盐或共晶体 |
| CN103179954A (zh) | 2010-09-02 | 2013-06-26 | 格吕伦塔尔有限公司 | 包含阴离子聚合物的抗破碎剂型 |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| EA033171B1 (ru) | 2011-03-04 | 2019-09-30 | Грюненталь Гмбх | Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол |
| WO2012119727A1 (en) | 2011-03-04 | 2012-09-13 | Grünenthal GmbH | Aqueous pharmaceutical formulation of tapentadol for oral administration |
| SI2680833T1 (sl) | 2011-03-04 | 2016-06-30 | Gruenenthal Gmbh | Parenteralno dajanje tapentadola |
| EP2694049B1 (en) | 2011-04-05 | 2018-10-31 | Grünenthal GmbH | Tapentadol for preventing chronification of pain |
| WO2012136351A1 (en) | 2011-04-05 | 2012-10-11 | Grünenthal GmbH | Tapentadol for treating pain associated with trigeminal neuralgia |
| HUE049308T2 (hu) | 2011-04-29 | 2020-09-28 | Gruenenthal Gmbh | Tapentadol alkalmazása depresszió és szorongás megelõzésére és kezelésére |
| HUE034711T2 (en) | 2011-07-29 | 2018-02-28 | Gruenenthal Gmbh | Anti-Abuse, Immediate Release Tablet |
| DK2736497T3 (da) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel. |
| AU2012289763B2 (en) | 2011-07-29 | 2017-07-13 | Grünenthal GmbH | Intrathecal or epidural administration of 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| EP2606879A1 (en) | 2011-12-21 | 2013-06-26 | Hexal AG | Multiple unit pellet tablet formulation comprising an opioid |
| AU2013225106B2 (en) | 2012-02-28 | 2017-11-02 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| AR090695A1 (es) | 2012-04-18 | 2014-12-03 | Gruenenthal Gmbh | Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| MX368846B (es) | 2013-07-12 | 2019-10-18 | Gruenenthal Gmbh | Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo. |
| EP2845625A1 (en) | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| EP2942054A1 (en) * | 2014-05-09 | 2015-11-11 | G.L. Pharma GmbH | Slow-release pharmaceutical formulation |
| CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
| CA2949422A1 (en) | 2014-05-26 | 2015-12-03 | Grunenthal Gmbh | Multiparticles safeguarded against ethanolic dose-dumping |
| KR20170132282A (ko) | 2015-03-27 | 2017-12-01 | 그뤼넨탈 게엠베하 | 타펜타돌의 비경구 투여를 위한 안정한 제형 |
| MX2017013637A (es) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes. |
| WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| EP3231420A1 (en) | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| ES3027562T3 (en) | 2016-09-23 | 2025-06-16 | Gruenenthal Gmbh | Stable formulation for parenteral administration of tapentadol |
| EP3585370A1 (en) | 2017-02-23 | 2020-01-01 | Grünenthal GmbH | Tapentadol as local anesthetic |
| ES2963929T3 (es) * | 2017-05-29 | 2024-04-03 | Gruenenthal Gmbh | Forma farmacéutica oral multipartículas que proporciona liberación prolongada de tapentadol |
| EP3875077B1 (en) | 2020-03-02 | 2023-12-13 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| EP3875080A1 (en) * | 2020-03-02 | 2021-09-08 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| PE20230105A1 (es) | 2020-03-02 | 2023-01-25 | Gruenenthal Chemie | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol |
| AU2020100441B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| AU2020100442B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| MX2022011505A (es) | 2020-03-16 | 2022-10-07 | Gruenenthal Gmbh | Comprimido ranurado. |
| DE202020104285U1 (de) | 2020-07-24 | 2020-12-18 | Grünenthal GmbH | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure |
| DE202020005470U1 (de) | 2020-11-10 | 2022-01-25 | Grünenthal GmbH | Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure |
| HUE059465T2 (hu) * | 2020-11-10 | 2022-11-28 | Gruenenthal Gmbh | A tapentadol L-(+)- borkõsav-só késleltetett felszabadulású adagolási formája |
| PE20240113A1 (es) | 2020-11-10 | 2024-01-22 | Gruenenthal Chemie | Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| DE2117239A1 (de) | 1971-04-08 | 1972-11-16 | König, Wilhelm, 4712 Werne | Verfahren zum Erstellen von Wänden aus Schalungssteinen |
| US4126672A (en) * | 1976-02-04 | 1978-11-21 | Hoffmann-La Roche Inc. | Sustained release pharmaceutical capsules |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
| US5601984A (en) | 1983-01-10 | 1997-02-11 | Gen-Probe Incorporated | Method for detecting, the presense or amount of a taxonomic group of organisms using specific R-RNA subsequences as probes |
| US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4783337A (en) * | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| GB8519310D0 (en) | 1985-07-31 | 1985-09-04 | Zyma Sa | Granular active substances |
| GB8626098D0 (en) * | 1986-10-31 | 1986-12-03 | Euro Celtique Sa | Controlled release hydromorphone composition |
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| ATE219933T1 (de) * | 1992-09-18 | 2002-07-15 | Yamanouchi Pharma Co Ltd | Hydrogelzubereitung mit verzögerter freisetzung |
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| DE4329794C2 (de) * | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
| WO1995014480A1 (fr) | 1993-11-17 | 1995-06-01 | Traditional Chinese Medicine Research Laboratory Inc. | Composition destinee au traitement de tissus presentant des lesions, procede de production et leur utilisation |
| US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
| US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
| CN1125572A (zh) * | 1994-12-28 | 1996-07-03 | 顺德市广容制药厂 | 一种罗通定痛释片的制作方法 |
| IL139728A (en) * | 1995-01-09 | 2003-06-24 | Penwest Pharmaceuticals Compan | Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient |
| DE19525137C2 (de) | 1995-07-11 | 2003-02-27 | Gruenenthal Gmbh | 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe |
| DE19609847A1 (de) | 1996-03-13 | 1997-09-18 | Gruenenthal Gmbh | Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe |
| US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
| EP0859603B1 (en) * | 1996-07-08 | 2008-12-17 | Penwest Pharmaceuticals Co. | Sustained release matrix for high-dose insoluble drugs |
| DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| AU729529B2 (en) * | 1997-06-06 | 2001-02-01 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| DE19901683B4 (de) | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
| EP2269587A1 (en) * | 1999-10-29 | 2011-01-05 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| DE10248309A1 (de) | 2002-10-16 | 2004-04-29 | Grünenthal GmbH | 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung |
-
2002
- 2002-10-18 PE PE2002001030A patent/PE20030527A1/es active IP Right Grant
- 2002-10-22 PT PT02781278T patent/PT1439829E/pt unknown
- 2002-10-22 PL PL369756A patent/PL216535B1/pl unknown
- 2002-10-22 NZ NZ532999A patent/NZ532999A/en not_active IP Right Cessation
- 2002-10-22 MX MXPA04003742A patent/MXPA04003742A/es active IP Right Grant
- 2002-10-22 JP JP2003537620A patent/JP4758064B2/ja not_active Expired - Lifetime
- 2002-10-22 ES ES02781278T patent/ES2248622T3/es not_active Expired - Lifetime
- 2002-10-22 IL IL16158702A patent/IL161587A0/xx unknown
- 2002-10-22 CA CA2464578A patent/CA2464578C/en not_active Expired - Lifetime
- 2002-10-22 DK DK02781278T patent/DK1439829T3/da active
- 2002-10-22 KR KR1020047006113A patent/KR100958045B1/ko not_active Expired - Lifetime
- 2002-10-22 DE DE50204198T patent/DE50204198D1/de not_active Expired - Lifetime
- 2002-10-22 WO PCT/EP2002/011806 patent/WO2003035054A1/de not_active Application Discontinuation
- 2002-10-22 SI SI200230224T patent/SI1439829T1/sl unknown
- 2002-10-22 HU HU0402104A patent/HU230161B1/hu unknown
- 2002-10-22 AT AT02781278T patent/ATE303802T1/de active
- 2002-10-22 BR BRPI0213653A patent/BRPI0213653B8/pt active IP Right Grant
- 2002-10-22 AU AU2002349001A patent/AU2002349001C1/en active Active
- 2002-10-22 EP EP02781278A patent/EP1439829B1/de not_active Expired - Lifetime
- 2002-10-22 WO PCT/EP2002/011809 patent/WO2003035053A1/de active IP Right Grant
- 2002-10-22 CN CNB028259769A patent/CN100402021C/zh not_active Expired - Lifetime
- 2002-10-23 AR ARP020104010A patent/AR036943A1/es not_active Application Discontinuation
- 2002-10-24 MY MYPI20023979A patent/MY127797A/en unknown
-
2004
- 2004-04-22 CO CO04037005A patent/CO5570662A2/es not_active Application Discontinuation
- 2004-04-22 IL IL161587A patent/IL161587A/en active IP Right Grant
- 2004-04-26 US US10/831,368 patent/US20050058706A1/en not_active Abandoned
- 2004-05-11 NO NO20041924A patent/NO331896B1/no not_active IP Right Cessation
- 2004-05-12 EC EC2004005102A patent/ECSP045102A/es unknown
- 2004-05-20 ZA ZA2004/03928A patent/ZA200403928B/en unknown
-
2010
- 2010-08-05 JP JP2010176084A patent/JP2010280697A/ja active Pending
-
2011
- 2011-09-23 US US13/242,800 patent/US20120034304A1/en not_active Abandoned
-
2012
- 2012-05-08 NO NO2012007C patent/NO2012007I2/no unknown
- 2012-08-13 CY CY2012022C patent/CY2012022I2/el unknown
-
2013
- 2013-04-23 US US13/868,635 patent/US20130237608A1/en not_active Abandoned
-
2016
- 2016-02-08 US US15/018,529 patent/US20160151309A1/en not_active Abandoned
- 2016-12-13 US US15/377,628 patent/US20170087103A1/en not_active Abandoned
-
2018
- 2018-04-02 US US15/943,175 patent/US20180221308A1/en not_active Abandoned
-
2019
- 2019-10-14 US US16/600,974 patent/US11007156B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2012022I1 (el) | Φαρμακο που περιεχει 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)φαινολη με επιβραδυμενη απελευθερωση δραστικης ουσιας | |
| NO20034419L (no) | Antifungalt preparat med forbedret biotilgjengelighet | |
| FI4823U1 (fi) | Muunnetulla tavalla vapauttava lääkeformulaatio | |
| DE50002776D1 (de) | Fungizide wirkstoffkombinationen | |
| DE50012448D1 (de) | Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol | |
| DE50014244D1 (de) | Pharmazeutische tramadolsalze | |
| DE60016271D1 (de) | Medikamentenzuführvorrichtung | |
| NO20030418L (no) | Nytt farmasöytisk preparat | |
| NO20041315L (no) | Medikamentavleveringssystem | |
| DE60126879D1 (de) | Anzeigegerät mit aktiver Matrix | |
| BRPI0013439B1 (pt) | composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante. | |
| ATE243933T1 (de) | Fungizide wirkstoffkombinationen | |
| NO20030627D0 (no) | Hydrogel-drevet medikament doseringsform | |
| NO20033143L (no) | Farmasoytisk preparat | |
| ATE428300T1 (de) | Fungizide wirkstoffkombinationen | |
| IT1319201B1 (it) | Farmaci per il diabete. | |
| DE50102752D1 (de) | Fungizide wirkstoffkombinationen | |
| DE50209245D1 (de) | Neuroprotektives medikament | |
| NO20025805L (no) | Farmasöytisk preparat | |
| DZ3495A1 (fr) | Formulations agrochimiques | |
| DK1294369T3 (da) | Hidtil ukendte formuleringer med alfa-2,4-disulfophenyl-N-tert-bytylnitron | |
| ATE276659T1 (de) | Fungizide wirkstoffkombinationen | |
| PT1200444E (pt) | Novos compostos xantona, sua preparacao e sua utilizacao como medicamento | |
| DE60129123D1 (de) | BIOLOGISCH AKTIVE 4H-BENZOi1,4öOXAZIN-3-ONE | |
| FR2820311B3 (fr) | Distributeur de medicament portatif |